Murray Lumpkin

2.0k total citations
27 papers, 782 citations indexed

About

Murray Lumpkin is a scholar working on Economics and Econometrics, Public Health, Environmental and Occupational Health and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Murray Lumpkin has authored 27 papers receiving a total of 782 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Economics and Econometrics, 6 papers in Public Health, Environmental and Occupational Health and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Murray Lumpkin's work include Pharmaceutical Economics and Policy (14 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Biomedical Ethics and Regulation (4 papers). Murray Lumpkin is often cited by papers focused on Pharmaceutical Economics and Policy (14 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Biomedical Ethics and Regulation (4 papers). Murray Lumpkin collaborates with scholars based in United States, United Kingdom and Switzerland. Murray Lumpkin's co-authors include Michael Friedman, Jeffrey Shuren, Janet Woodcock, Larry J. Thompson, Vincent I. Ahonkhai, John C. W. Lim, Dan Hartman, Hubert G. M. Leufkens, Mike Ward and Ajoy C. Chakrabarti and has published in prestigious journals such as Science, JAMA and PLoS ONE.

In The Last Decade

Murray Lumpkin

27 papers receiving 715 citations

Peers

Murray Lumpkin

PHEOH

PPCH

PHARM

SURGE

Euni Lee South Korea

Cassyano Januário Correr Brazil

Jimmy José Oman

Mitja Kos Slovenia

Abdulla Shehab United Arab Emirates

Makiko Kusama Japan

Renee Robinson United States

Al‐Motassem Yousef Jordan

Caroline Morris New Zealand

Eyob Alemayehu Gebreyohannes Ethiopia

Euni Lee South Korea

Murray Lumpkin

123 ×0.5

170 ×1.3

PHEOH

122 ×1.0

PPCH

65 ×0.6

PHARM

87 ×1.1

SURGE

Citations per year, relative to Murray Lumpkin Murray Lumpkin (= 1×) peers Euni Lee

Countries citing papers authored by Murray Lumpkin

Since Specialization

Citations

This map shows the geographic impact of Murray Lumpkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murray Lumpkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murray Lumpkin more than expected).

Fields of papers citing papers by Murray Lumpkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murray Lumpkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murray Lumpkin. The network helps show where Murray Lumpkin may publish in the future.

Co-authorship network of co-authors of Murray Lumpkin

This figure shows the co-authorship network connecting the top 25 collaborators of Murray Lumpkin. A scholar is included among the top collaborators of Murray Lumpkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murray Lumpkin. Murray Lumpkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cavaleri, Marco, Adam Hacker, Murray Lumpkin, et al.. (2025). A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systems. The Lancet Global Health. 13(4). e769–e777. 6 indexed citations

McNair, Douglas, et al.. (2021). Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World. Clinical Pharmacology & Therapeutics. 111(1). 44–51. 13 indexed citations

Sillo, Hiiti, Aggrey Ambali, Eliangiringa Kaale, et al.. (2020). Coming together to improve access to medicines: The genesis of the East African Community’s Medicines Regulatory Harmonization initiative. PLoS Medicine. 17(8). e1003133–e1003133. 21 indexed citations

Chakrabarti, Ajoy C., et al.. (2020). Navigating facilitated regulatory pathways during a disease X pandemic. npj Vaccines. 5(1). 101–101. 26 indexed citations

Hafner, Tamara, Jillian Clare Köhler, Zaheer‐Ud‐Din Babar, et al.. (2020). Integrating pharmaceutical systems strengthening in the current global health scenario: three ‘uncomfortable truths’. Journal of Pharmaceutical Policy and Practice. 13(1). 38–38. 7 indexed citations

Lumpkin, Murray & John C. W. Lim. (2020). Pandemic Best Regulatory Practices: An Urgent Need in the COVID‐19 Pandemic. Clinical Pharmacology & Therapeutics. 108(4). 703–705. 11 indexed citations

Bempong, Daniel K., Joseph B. Babigumira, Shabir Banoo, et al.. (2018). Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems. Globalization and Health. 14(1). 102–102. 72 indexed citations

Morgan, Steven G., et al.. (2017). The cost of entry: An analysis of pharmaceutical registration fees in low-, middle-, and high-income countries. PLoS ONE. 12(8). e0182742–e0182742. 8 indexed citations

Lumpkin, Murray, et al.. (2017). Optimized Medical Product Regulation in Mexico: A Win-Win for Public and Economic Health. Therapeutic Innovation & Regulatory Science. 51(6). 744–750. 3 indexed citations

10.

Ahonkhai, Vincent I., et al.. (2016). Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization. PLoS ONE. 11(11). e0166515–e0166515. 50 indexed citations

11.

Liberti, Lawrence, Alasdair Breckenridge, Jarno Hoekman, et al.. (2016). Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities. Journal of Public Health Policy. 37(3). 315–333. 18 indexed citations

12.

Hirsch, Gigi, Mark Trusheim, M Bala, et al.. (2016). Adaptive Biomedical Innovation: Evolving Our Global System to Sustainably and Safely Bring New Medicines to Patients in Need. Clinical Pharmacology & Therapeutics. 100(6). 685–698. 9 indexed citations

13.

Baird, Lynn G., Mark Trusheim, Murray Lumpkin, et al.. (2015). Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation. Therapeutic Innovation & Regulatory Science. 50(3). 347–354. 11 indexed citations

14.

Lumpkin, Murray, et al.. (2012). Advancing the Science of Medicines Regulation: The Role of the 21st-Century Medicines Regulator. Clinical Pharmacology & Therapeutics. 92(4). 486–93. 21 indexed citations

15.

Claassen, Cynthia A., et al.. (2000). Toward a redefinition of psychiatric emergency.. PubMed. 35(3). 735–54. 24 indexed citations

16.

Lumpkin, Murray. (2000). International Pharmacovigilance: Developing Cooperation to Meet the Challenges of the 21st Century. Pharmacology & Toxicology. 86(s1). 20–22. 7 indexed citations

17.

Friedman, Michael, et al.. (1999). The Safety of Newly Approved Medicines. JAMA. 281(18). 1728–1728. 176 indexed citations

18.

Lumpkin, Murray. (1998). FDA public health advisory: Low molecular-weight heparin and spinal/epidural anesthesia or spinal puncture. PubMed. 4(2). 56–57. 6 indexed citations

19.

Lumpkin, Murray. (1994). Safety alert: Hazards of precipitation associated with parenteral nutrition. American Journal of Health-System Pharmacy. 51(11). 1427–1428. 100 indexed citations

20.

Lumpkin, Murray. (1994). Clinical trials from a regulator's perspective. Infection. 22(S1). S61–S64. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact